Treatment of hypertension in renal transplant recipients

Current Opinion in Urology

Volumn 13, Issue 2, 2003, Pages 91-98

  Tylicki, Leszek ^a   Habicht, Antje ^b   Watschinger, Bruno ^b   Hörl, Walter H ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hypertension; Kidney; Renal transplantation; Treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ALLOGRAFT; BLOOD PRESSURE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ARTERY STENOSIS; KIDNEY TRANSPLANTATION; NEPHRECTOMY; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; HYPERTENSION, RENOVASCULAR; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; NEPHRECTOMY; RENAL ARTERY OBSTRUCTION;

EID: 0037336666     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200303000-00002     Document Type: Review

References (114)

1. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines subcommittee. J Hypertens 1999; 17:151-183.
2. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
3. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 (Suppl 15):S1-S86.
4. Mammen NI, Chacko N, Ganesh G, et al. Aspects of hypertension in renal allograft recipients: a study of 1000 live renal transplants. Br J Urol 1993; 71:256-258.
5. Jarowenko MV, Flechner SM, Van Buren CT, et al. Influence of cyclosporine on posttransplant blood pressure response. Am J Kidney Dis 1987; 10:98-103.
6. Zeier M, Mandelbaum A, Ritz E. Hypertension in the transplanted patient. Nephron 1998; 80:257-268.
7. First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4 (Suppl 8):S30-S36.
8. Rosenkranz AR, Mayer G. Mechanisms of hypertension after renal transplantation. Curr Opin Urol 2000; 10:81-86.
9. Midtvedt K, Hartmann A. Hypertension after kidney transplantation: are treatment guidelines emerging? Nephrol Dial Transplant 2002; 17:1166-1169.
10. Budde K, Waiser J, Fritsche L, et al. Hypertension in patients after renal transplantation. Transplant Proc 1997; 29:209-211.
11. Perez Fontan M, Rodriguez-Carmona A, Garcia Falcon T, et al. Early immunologic and nonimmunologic predictors of arterial hypertension after renal transplantation. Am J Kidney Dis 1999; 33:21-28.
12. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57:307-313.
13. Massy ZA. Cardiovascular risk factors in kidney transplantation. Curr Opin Urol 2001; 11:139-142.
14. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7:158-165.
15. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999; 14:648-654.
16. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982; 248:1465-1477.
17. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the national stroke association. JAMA 1999; 281:1112-1120.
18. Tomita J, Kimura G, Inoue T, et al. Role of systolic blood pressure in determining prognosis of hemodialyzed patients. Am J Kidney Dis 1995; 25:405-412.
19. Fournier A, el Esper N, Makdassi R, et al. Hypertension and progression of renal insufficiency. Nephrol Dial Transplant 1994; 9:28-34.
20. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the modification of diet in renal disease study. Ann Intern Med 1995; 123:754-762.
21. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure: collaborative transplant study. Kidney Int 1998; 53:217-222.
22. Frei U, Schindler R, Wieters D, et al. Pre-transplant hypertension: a major risk factor for chronic progressive renal allograft dysfunction? Nephrol Dial Transplant 1995; 10:1206-1211.
23. Hjelmesaeth J, Hartmann A, Midtvedt K, et al. Metabolic cardiovascular syndrome after renal transplantation. Nephrol Dial Transplant 2001; 16:1047-1052.
24. Cohen D, Galbraith C. General health management and long-term care of the renal transplant recipient. Am J Kidney Dis 2001; 38 (Suppl 6):S10-S24.
25. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988; 85:134-138.
26. Schweitzer EJ, Matas AJ, Gillingham KJ, et al. Causes of renal allograft loss: progress in the 1980s, challenges for the 1990s. Ann Surg 1991; 214:679-688.
27. Olyaei AJ, deMattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients. Drugs 1999; 58:1011-1027.
28. Mailloux LU, Levey AS, Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl 3):S120-S141.
29. European best practice guidelines for renal transplantation (part 2): arterial hypertension. Nephrol Dial Transplant 2002; 17 (Suppl 4):S25-S26. Comprehensive guidelines for the long-term management of RTRs. The recommendations were supported by the European Renal Association, the European Society for Organ Transplantation and the European Society of Paediatric Nephrology.
30. Calzolari A, Giordano U, Matteucci MC, et al. Hypertension in young patients after renal transplantation: ambulatory blood pressure monitoring versus casual blood pressure. Am J Hypertens 1998; 11:497-501.
31. van den Dorpel MA, van den Meiracker AH, Lameris TW, et al. Cyclosporin A impairs the nocturnal blood pressure fall in renal transplant recipients. Hypertension 1996; 28:304-307.
32. de Mattos AM, Olyaei AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996; 28:631-667.
33. Sketris IS, Methot ME, Nicol D, et al. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. Ann Pharmacother 1994; 28:1227-1231.
34. Guan D, Wang R, Lu J, et al. Effects of nicardipine on blood cyclosporine levels in renal transplant patients. Transplant Proc 1996; 28:1311-1312.
35. Pesavento TE, Jones PA, Julian BA, Curtis JJ. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol 1996; 7:831-835.
36. McGregor DO, Bailey RR, Robson RA. Amlodipine has a minor effect on cyclosporine metabolism [letter]. Clin Nephrol 1997; 48:336.
37. Kaijser M, Johnsson C, Zezina L, et al. Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clin Transplant 1997; 11:577-581.
38. West C, Carpenter BJ, Hakala TR. The incidence of gout in renal transplant recipients. Am J Kidney Dis 1987; 10:369-372.
39. Hoes AW, Grobbee DE, Lubsen J, et al. Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995; 123:481-487.
40. Schmidt A, Gruber U, Bohmig G, et al. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CSA. Nephrol Dial Transplant 2001; 16:1034-1037.
41. Tripathi M, Kaushik S, Gaur A, Kher V. Effect of antihypertensives on plasma potassium in end stage renal disease: a retrospective study. J Indian Med Assoc 1997; 95:543-545.
42. Schwarzbeck A, Wittenmeier KW, Hallfritzsch U. Anaemia in dialysis patients as a side-effect of sartanes [letter]. Lancet 1998; 352:286.
43. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33:829-839.
44. Raman GV. Post transplant hypertension. J Hum Hypertens 1991; 5:1-6.
45. Haas M, Mayer G. Cyclosporin A-associated hypertension: pathomechanisms and clinical consequences. Nephrol Dial Transplant 1997; 12:395-398.
46. Curtis JJ, Galla JH, Kotchen TA, et al. Prevalence of hypertension in a renal transplant population on alternate-day steroid therapy. Clin Nephrol 1976; 5:123-127.
47. Hricik DE, Kupin WL, First MR. Steroid-free immunosuppression after renal transplantation. J Am Soc Nephrol 1994; 4 (Suppl):S10-S16.
48. Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 1998; 30:1216-1218.
49. Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359:741-746.
50. Henry ML. Cyclosporine and tacrolimus (FK 506): a comparison of efficacy and safety profiles. Clin Transplant 1999; 13:209-220.
51. Schwarz C, Oberbauer R. The future role of target of rapamycin inhibitors in renal transplantation. Curr Opin Urol 2002; 12:109-113.
52. Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation 2001; 71 (Suppl):SS42-SS51.
53. Midtvedt K, Neumayer HH. Management strategies for posttransplant hypertension. Transplantation 2000; 70 (Suppl): SS64-SS69.
54. Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43:706-711.
55. McCulloch TA, Harper SJ, Donnelly PK, et al. Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. J Clin Pathol 1994; 47:839-842.
56. Birx DL, Berger M, Fleisher TA. The interference of T cell activation by calcium channel blocking agents. J Immunol 1984; 133:2904-2909.
57. Palmer BF, Dawidson I, Sagalowsky A, et al. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 1991; 52:640-645.
58. Ladefoged SD, Andersen CB. Calcium channel blockers in kidney transplantation. Clin Transplant 1994; 8:128-133.
59. Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72:1787-1792. The authors found that CCB was superior to ACEI for treatment of early posttransplant hypertension. Patients receiving nifedipine but not lisinopril improved kidney transplant function over a period of 2 years.
60. Rahn KH, Barenbrock M, Fritschka E, et al. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet 1999; 354:1415-1420.
61. Dudley CR. Treatment of posttransplant hypertension: ACE is trumped? Transplantation 2001; 72:1728-1729.
62. Epstein M. Calcium antagonists and renal disease. Kidney Int 1998; 54:1771-1784.
63. Stigant CE, Cohen J, Vivera M, Zaltzman JS. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35:58-63.
64. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
65. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869. Randomized, double-blind study, which showed that losartan displayed clear nephroprotective activity in patients with diabetic nephropathy.
66. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-945.
67. de Jong PE, Anderson S, de Zeeuw D. Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome? J Am Soc Nephrol 1993; 3:1333-1341.
68. Ruiz-Ortega M, Lorenzo O, Ruperez M, Egido J. ACE inhibitors and AT1 receptor antagonists: beyond the haemodynamic effect. Nephrol Dial Transplant 2000; 15:561-565.
69. Szabo A, Lutz J, Schleimer K. et al. Effect of angiotensin-converting enzyme inhibition on growth factor MRNA in chronic renal allograft rejection in the rat. Kidney Int 2000; 57:982-991.
70. Inigo P, Campistol JM, Lario S, et al. Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-beta(1) plasma levels in a crossover trial in renal transplant recipients. J Am Soc Nephrol 2001; 12:822-827.
71. Rell K, Linde J, Morzycka-Michalik M, et al. Effect of enalapril on proteinuria after kidney transplantation. Transplant Int 1993; 6:213-217.
72. Navarro JF, Macia ML, Garcia J. Control of severe proteinuria with losartan after renal transplantation. Am J Nephrol 1998; 18:261-262.
73. Wirta O, Pasternack A, Muslonen J, et al. Nephrotic syndrome, hyperrenihemia and multiple transplant renal arterial stenoses in a patient with diabetes. Nephron 1998; 78:481-484.
74. Tylicki L, Rutkowski P, Renke M, Rutkowski B. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Am J Nephrol 2002; 22:356-362.
75. Matteucci E, Carmellini M, Bertoni C, et al. Urinary excretion rates of multiple renal indicators after kidney transplantation: clinical significance for early graft outcome. Ren Fail 1998; 20:325-330.
76. Lin J, Valeri AM, Markowitz GS, et al. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002; 73:783-788. This is an important retrospective study, which examines the effects of ACEIs and ARAs on progression of chronic allograft nephropathy. The study shows a decreased incidence and slower rate of progression of renal insufficiency in patients treated with these drugs.
77. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The solvd investigators. N Engl J Med 1991; 325:293-302.
78. Ducloux D, Fournier V, Bresson-Vautrin C, Chalopin JM. Treatment of posttransplant erythrocytosis with losartan. Transplant Proc 1997; 29:2407-2408.
79. Montanaro D, Groupuzzo M, Boscutti G, et al. Long-term therapy for postrenal transprant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms. Clin Nephrol 2000; 53:47-51.
80. Curtis JJ. Management of hypertension after transplantation. Kidney Int Suppl 1993; 43:S45-S49.
81. Ahmad T, Coulthard MG, Eastham EJ. Reversible renal failure due to the use of captopril in a renal allograft recipient treated with cyclosporin. Nephrol Dial Transplant 1989; 4:311-312.
82. del Castillo D, Campistol JM, Guirado L, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 1998; 68:S135-S139.
83. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43:419-425.
84. Suter PM, Vetter W. Metabolic effects of antihypertensive drugs. J Hypertens Suppl 1995; 13:S11-S17.
85. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities study. N Engl J Med 2000; 342:905-912.
86. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. The Beta-Blocker Pooling Project Research Group. Eur Heart J 1988; 9:8-16.
87. Poole-Wilson PA, Cleland JG, Di Lenarda A, et al. Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Eur J Heart Fail 2002; 4:321-329.
88. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
89. Zezina L, Vessby B, Larsson E, et al. Carvedilol treatment of kidney graft ecipients with chronic rejection. Clin Transplant 1999; 13:484-490.
90. Wong VY, Laping NJ, Nelson AH, et al. Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Br J Pharmacol 2001; 134:977-984.
91. Brooks DP, Short BG, Cyronak MJ, et al. Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Br J Pharmacol 1993; 109:581-586.
92. Calo L, Giacon B, Davis PA, et al. Oxidative stress and TGFbeta in kidney-transplanted patients with cyclosporin-induced hypertension: effect of carvedilol and nifedipine. Clin Nephrol 2002; 58:103-110. The authors suggest that carvedilol may prevent endothelial dysfunction, fibrogenesis and post-transplant nephropathy by decreasing nitric oxide degradation and production of TGF-β.
93. Yue TL, Wang X, Gu JL, et al. Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol 1995; 294:585-591.
94. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 1993; 90:6189-6193.
95. Converse Jr RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918.
96. Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol 2000; 11:1469-1478.
97. Krespi P, Makris T, Hatzizacharias A, et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12:463-467.
98. Bauduceau B, Mayaudon H, Dupuy O. Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril. J Cardiovasc Risk 2000; 7:57-61.
99. Strojek K, Grzeszczak W, Gorska J, et al. Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001; 12:602-605. A randomized, crossover, placebo control study, which demonstrated antialbuminuric effect of nonhypotensive doses of centrally acting antihypertensive agent, moxonidine.
100. Martinez-Castelao A, Hueso M, Sanz V, et al. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int Suppl 1998; 68:S130-S134.
101. Krusell LR, Christensen CK, Pedersen OL. Alpha-adrenoceptor blockade in patients with mild to moderate hypertension: long-term renal effects of doxazosin. J Cardiovasc Pharmacol 1992; 20:440-444.
102. Young RA, Brogden RN. Doxazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Drugs 1988; 35:525-541.
103. Andersson PE, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men: relationship to changes in skeletal muscle blood flow. Am J Hypertens 1996; 9:323-333.
104. Kew CE II, Curtis JJ. The best way to manage hypertension after renal transplantation. J Ren Nutr 2000; 10:3-6.
105. Sankari BR, Geisinger M, Zelch M, et al. Post-transplant renal artery stenosis: impact of therapy on long-term kidney function and blood pressure control. J Urol 1996; 155:1860-1864.
106. Schwenger V, Zeier M, Ritz E. Hypertension after renal transplantation. Curr Hypertens Rep 2001; 3:434-439.
107. Dong Q, Schoenberg SO, Carlos RC, et al. Diagnosis of renal vascular disease with MR angiography. Radiographics 1999; 19:1535-1554.
108. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001; 344:431-442.
109. Newman-Sanders AP, Gedroyc WG, al-Kutoubi MA, et al. The use of expandable metal stents in transplant renal artery stenosis. Clin Radiol 1995; 50:245-250.
110. Curtis JJ, Luke RG, Diethelm AG, et al. Benefits of removal of native kidneys in hypertension after renal transplantation. Lancet 1985; 2:739-742.
111. Yasumura T, Oka T, Aikawa I, et al. Beneficial effect of bilateral native nephrectomy on long-term survival of living related kidney allografts. Transplant Proc 1989; 21:1967-1969.
112. Fricke L, Doehn C, Steinhoff J, et al. Treatment of posttransplant hypertension by laparoscopic bilateral nephrectomy? Transplantation 1998; 65:1182-1187.
113. Midtvedt K, Hatmann A, Bentdal O, et al. Bilateral nephrectomy simultaneously with renal allografting does not alleviate hypertension 3 months following living-donor transplantation. Nephrol Dial Transplant 1996; 11:2045-2049.
114. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.